TNXP - Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December | Benzinga
CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Tonix Management will present and host investor meetings at the following December investor conferences:
NobleCon 19, Noble Capital Markets' 19th Annual Emerging Growth Equity Conference
| Presenter: |
| Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals |
| Date: |
| Monday, December 4, 2023 |
| Place: |
| Florida Atlantic University, Boca Raton, Fla. |
| Room: |
| Presentation Room 1 |
| Time: |
| 11:00 a.m. ET |
December 2023 Virtual Investor Summit
| Presenter: |
| Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals |
| Date: |
| Thursday, December 7, 2023 |
| Time: |
| 12:00 p.m. ET |
| Webcast Link: |
| HERE |
Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators. Replays of both webcasts of the Company's presentations at NobleCon 19 and the Virtual Investor Summit will be available under the IR Events tab of the Tonix website at www.tonixpharma.com following each presentation.
Tonix Pharmaceuticals Holding Corp.*
Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without ...